Crinetics Pharmaceuticals, Inc. (CRNX)
| Market Cap | 4.14B |
| Revenue (ttm) | 7.70M |
| Net Income (ttm) | -465.32M |
| Shares Out | 104.71M |
| EPS (ttm) | -4.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,089,771 |
| Open | 40.47 |
| Previous Close | 40.12 |
| Day's Range | 39.22 - 40.50 |
| 52-Week Range | 24.10 - 57.99 |
| Beta | 0.24 |
| Analysts | Strong Buy |
| Price Target | 74.78 (+89.27%) |
| Earnings Date | Feb 26, 2026 |
About CRNX
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candida... [Read more]
Financial Performance
In 2025, Crinetics Pharmaceuticals's revenue was $7.70 million, an increase of 640.71% compared to the previous year's $1.04 million. Losses were -$465.32 million, 55.9% more than in 2024.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for CRNX stock is "Strong Buy." The 12-month stock price target is $74.78, which is an increase of 89.27% from the latest price.
News
Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the following two upcoming investor conferences...
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, Februar...
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
SAN DIEGO, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating investig...
Crinetics Pharmaceuticals, Inc. (CRNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Crinetics Pharmaceuticals, Inc. (CRNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2026, the Compensation Committee of the Board of Directors granted non-q...
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of novel...
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of novel...
Crinetics Pharmaceuticals, Inc. (CRNX) Discusses PALSONIFY Launch Progress and Phase 2 Atumelnant Results in Congenital Adrenal Hyperplasia Transcript
Crinetics Pharmaceuticals, Inc. (CRNX) Discusses PALSONIFY Launch Progress and Phase 2 Atumelnant Results in Congenital Adrenal Hyperplasia Transcript
Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia
Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Atumelnant (8...
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30...
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will pr...
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and clinical measures of CAH Phase 3 study builds on positive phase 2 results showing ...
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Dec. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2025, the Compensation Committee of the Board of Directors granted non...
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with...
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
CAREFNDR underscores the potential clinical value of p altusotine b eyond acromegaly, and demonstrates progress in Crinetics' commitment to addressing unmet needs in the neuroendocrine tumor community...
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2025, the Compensation Committee of the Board of Directors granted non-...
Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2025 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc. ( CRNX) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Gayathri Diwakar - Senior Director of Investor Relations R. Struthers - Founder, Presid...
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
PALSONIFY™ (Paltusotine) Launched in the U.S. with Encouraging Early Feedback from Patients and Physicians, and Positive Reimbursement Trends Reiterates Cash Burn of $340-370M and Cash Runway in...
Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
Preliminary analysis of one-year progression-free survival data from Phase 2 study of novel SST2 agonist paltusotine under investigation for carcinoid syndrome demonstrated potential anti-tumor effect...
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2025, the Compensation Committee of the Board of Directors granted non-q...
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025 after...
Crinetics: FDA Approval And Expansion Of Palsonify In Focus, Maintaining 'Buy' Rating
Crinetics Pharmaceuticals received FDA approval for PALSONIFY, the first daily oral therapy for adults with Acromegaly, addressing a large unmet need. The company has submitted a Marketing Authorizati...
Crinetics Pharmaceuticals, Inc. - Special Call
Crinetics Pharmaceuticals, Inc. - Special Call Company Participants Gayathri Diwakar - Senior Director of Investor Relations R. Struthers - Founder, President, CEO & Director Dana Pizzuti - Chief Medi...